Is Allergy Therapeutics PLC halal to invest in?

As of July 2026, Allergy Therapeutics PLC AGY.L is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Allergy Therapeutics PLC a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Allergy Therapeutics PLC using these criteria to determine its compliance status.

Can Muslims buy shares of Allergy Therapeutics PLC?

Muslim investors may consider investing in Allergy Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Allergy Therapeutics PLC classified as HALAL?

Musaffa determines the Shariah status of Allergy Therapeutics PLC by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Allergy Therapeutics PLC updated?

The Shariah compliance status of Allergy Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Allergy Therapeutics PLC become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Allergy Therapeutics PLC?

You can check the latest Shariah compliance status of Allergy Therapeutics PLC on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Allergy Therapeutics PLC AGY.L

Last Updated: Jul 20, 12:00 AM·LSE

AGY.L Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Allergy Therapeutics PLC is classified as halal.

HALAL

Report Source: 2025 Annual Report

Allergy Therapeutics PLC. Stock Analysis AGY.L

United Kingdom Health Care Small Cap Report: 2025 Annual

Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The firm is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. The company sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.

Key Statistics of Allergy Therapeutics PLC (AGY.L)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

GBX6.50GBX6.92

Today's Open

GBX6.55

Volume

16.19K

P/E Ratio (TTM)

52 Week Range

GBX6.00GBX12.10

Market Cap

41.79B

Avg. Volume

61.55K

Dividend Yield

Financial Metrics & Statements of Allergy Therapeutics PLC (AGY.L)

Super Investors Invested in Allergy Therapeutics PLC (AGY.L)

FAQ's for Allergy Therapeutics PLC (AGY.L)

As of July 2026, Allergy Therapeutics PLC AGY.L is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Allergy Therapeutics PLC using these criteria to determine its compliance status.
Muslim investors may consider investing in Allergy Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Allergy Therapeutics PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Allergy Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Allergy Therapeutics PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.